The G-protein coupled metabotropic glutamate receptors (GRMs/mGluRs) have been implicated in the aetiology of schizophrenia as they modulate the NMDA response and that of other neurotransmitters including dopamine and GABA.
The G-protein coupled metabotropic glutamate receptors (GRMs/mGluRs) have been implicated in the aetiology of schizophrenia as they modulate the NMDA response and that of other neurotransmitters including dopamine and GABA. [1] [2] [3] Electrophysiological studies in GRM subtype 5 knockout mice reveal, in one study, a sensorimotor gating deficit characteristic of schizophrenia 4 and in another, a key rô le for this gene in the modulation of hippocampal NMDA-dependent synaptic plasticity. 5 In humans, GRM5 levels are increased in certain pyramidal cell neurons in schizophrenics vs controls. 6 Finally, GRM5 has been mapped to 11q14, neighbouring a translocation that segregates with schizophrenia and related psychoses in a large Scottish family, F23 (MLOD score 6.0). 7, 8 We determined the intron/exon structure of GRM5 and identified a novel intragenic microsatellite. A case-control association study identified a significant difference in allele frequency distribution between schizophrenics and controls (P = 0.04). This is suggestive of involvement of the GRM5 gene in schizophrenia in this population. Molecular Psychiatry (2001) 6, 311-314.
The ability to implicate a particular candidate gene in the aetiology of a disease using association studies is largely dependent on the availability of polymorphic markers that are in linkage disequilibrium with the causative mutation. The GRM5 gene has previously been localised by radiation hybrid mapping alone, and as such its physical distance from any previously identified polymorphisms is unknown. We have previously mapped the GRM5 gene to more than 850 kb from the t(1;11) translocation breakpoint; 9 however there is a paucity of genes in this genomic region 10, 11 and the GRM5 gene remains the best functional candidate gene on chromosome 11 for involvement in the aetiology of psychiatric illness in this family. We therefore set out to characterise the genomic organisation of the GRM5 gene to permit identification of intragenic mutations/polymorphisms (within the exons or flanking intron sequences) with which to test for association in our sample of patients with schizophrenia and bipolar affective disorder.
BLAST 12 searching with the complete cDNA sequence of the GRM5a gene (Accession number D28538) against the High Throughput Genomic Sequences (HTGS) portion of the Genbank database, together with analysis of the Washington University Human BAC fingerprint database, enabled identification of 13 positive bacterial artificial chromosomes (BACs; Accession numbers AC026168, AC024733,  AC022014,  AC022005,  AP000626,  AC026078,  AC027127, AC034188, AC026201, AC022004, AP001828, AP000653, and AC022006). Scrutiny of the exact regions of sequence identity between the cDNA and BAC sequence enabled the complete intron/exon structure of the GRM5 gene to be determined. All intron/exon boundaries were present in multiple BACs with no inconsistencies except the 3Ј end of exon 1, which was represented in a single BAC only. However, this and all the other boundaries also exhibited splice site consensus sequences, which conformed to the consensus dinucleotides AG at the 3Ј end of each intron and GT at the 5Ј end (data not shown). The gene is present as 8 exons in genomic DNA, with exons ranging in size from 127 bp (exon 6) to 1738 bp (exon 8). The position of the final intron/exon boundary and existence of the large single exon at the 3Ј end of the gene is consistent with the previous findings of Daggett et al. 13 The genomic organisation of this gene is shown in Figure 1 .
Since the BAC sequence from which the genomic organisation was established is still fragmentary, it was not immediately possible to determine the size of each intron. Therefore the sequence fragments from each BAC were assembled into contigs as far as possible. Three contigs contained multiple exons of the GRM5 gene, enabling the exact genomic distance between exons 3 to 8 to be calculated ( Figure 1 ). The contigs containing exons 1 and 2 did not contain other exons, so it was possible only to calculate minimum intron sizes. GRM5 is a large gene, spanning at least Two sets of DNAs were used for scanning exons of the GRM5 gene for mutations/polymorphisms. Firstly normal control DNAs (n = 27) were studied to identify common polymorphisms for use in association studies. The power of this study to detect polymorphisms with at least a 5% frequency is 94%. Secondly, two F23 derived DNAs were investigated with the aim of identifying mutations which may have been fixed by, and segregate with the translocation in this family. 7 Primer pairs were designed from intronic BAC sequence flanking exons 1-7, such that each exon could be amplified independently from genomic DNA. Since exons 1 and 7 are large, more than one primer pair was required to permit amplification of the exon in overlapping fragments of a size suitable for mutation detection (Ͻ500 bp). PCR products were then subjected to mutation detection by denaturing high performance liquid chromatography (DHPLC). No sequence variants were detected. Since DHPLC is a highly sensitive method for mutation detection, 14, 15 it is unlikely that there are any common polymorphisms or mutations in the exons tested.
To detect intragenic polymorphisms for association studies, the available intron sequence was searched for simple repeats using Repeat Masker. 16 Many different types of simple repeat were detected, including (CA)n and (TA)n dinucleotide repeats and a (TAA)n triplet repeat. Since longer stretches of repetitive sequence are more likely to be polymorphic, a CA repeat of 16 repeat units was chosen for further study. This CA repeat was identified from BAC AC022014, beginning 16245 bp upstream of exon 7 (nucleotide position 70312 in the BAC sequence). A PCR assay was designed and optimised to amplify a 203-bp fragment that contained this CA repeat. Twelve different individuals were assayed and the products sized on a capillary gel electrophoresis system (AB1310). Five different allele sizes were observed within this small set of subjects, and so the microsatellite was deemed sufficiently polymorphic for use in an association study. This microsatellite has been submitted to dbSTS with the Accession number G64931.
To test the hypothesis that the GRM5 gene might contribute to psychosis in the general population, we carried out a case-control association study by microsatellite typing in patient populations with schizophrenia (n = 231) or bipolar affective disorder (n = 149), and normal controls (n = 421). A total of 11 differently sized alleles was present in the total sample (represented as PCR products of sizes 191, 192, 196, 197, 199, 200, 201, 203, 205, 206 and 207 bp) . This range of allele sizes suggested that this locus is more complex than a simple (CA) repeating unit. This was confirmed by direct sequencing of PCR products from individuals homozygous for the 199, 200 and 201-bp alleles. Individuals homozygous for the 199 and 201-bp alleles differed by 1 (CA) repeat unit as expected, whereas the individual homozygous for the 200-bp allele also harboured a deletion of a single adenine nucleotide from a stretch of 6 occurring 31 bp upstream of the CA repeat. It is presumed that the combination of the CA repeat plus either 5 or 6 adenines at −31 bp accounts for the range of allele sizes observed.
The frequency of each allele in the different populations is shown in Table 1 . The distribution of allele frequencies is significantly different between schizo- 17 advised that the 2 approximation is safe provided that no expected frequency is Ͻ1 and roughly no more than two in 10 of the remaining cells have expected frequencies Ͻ5. So the value of 2 = 13.49 (6 degrees of freedom, P = 0.036) should be interpreted with a degree of caution. As an additional test of significance, a simulation of the reduced (7 × 2) contingency table was carried out with 2 statistics being calculated for each of 104 replications. The number of values of 2 Ͼ 13.49 was 457, equivalent to a significance level of P = 0.046. The greatest contribution to the chi-squared total comes from the 197-bp allele, which is found only in schizophrenics, albeit at a low frequency (1.3%). However since no control individuals possess a 197-bp allele, it is not possible to calculate a meaningful relative risk. The 201-bp allele not the 197-bp allele was present in the F23 individual tested, hence it does not confer susceptibility to psychosis in this family.
These results are consistent with a rô le for the GRM5 gene in the aetiology of schizophrenia in a small proportion of our sample. The microsatellite repeat used to detect the positive association occurs within an intron of the GRM5 gene, and may comprise part of a hitherto unrecognised control element involved in splicing or mRNA stability. It is more likely however that the microsatellite is in linkage disequilibrium with a causative mutation, and further studies will be required to detect functional polymorphisms in those individuals carrying the 197-bp allele.
The results of previous linkage studies for psychiatric illness in this region of chromosome 11 have yielded ambivalent results. Three genome scans have detected moderate positive LOD scores (Ն1), [18] [19] [20] and a fourth in a single family yielded a maximum LOD score of 3.41, 21 but in each case maximum linkage was obtained with markers on 11q22-24, telomeric to GRM5. Other linkage studies have in contrast yielded negative results. 22, 23 The previous failure to find linkage in the region of the GRM5 gene may be related to the small effect size seen in this study and illustrates the power of the association approach for such susceptibility loci. A more extensive survey in different cohorts and populations, to determine whether the 197-bp allele is found exclusively in 'at risk' individuals, is now warranted.
Materials and methods

Clinical samples
Subjects with major mental illness were inpatients or outpatients of the Royal Edinburgh Hospital or Hairmyres Hospital, Lanarkshire and gave written consent Molecular Psychiatry to take part in these studies. For inclusion in the association studies patients had to be domiciled in the South of Scotland and of Scottish descent. Subjects with mental illness were interviewed by a psychiatrist using the Schedule for Affective Disorders and Schizophrenia, SADS-L. 24 Hospital cases were coded using OPCRIT 25 and diagnoses were made according to DSM III-R and DSM-IV criteria. DNA from control subjects was obtained through the Edinburgh and SE Scotland Blood Transfusion Service. Donors were asked to complete a screening questionnaire and subjects taking regular medication or with a present or past history of serious illness were excluded. No details were obtained on family history of illnesses in controls.
Extraction and PCR of genomic DNA DNA was extracted from whole blood using a Nucleon genomic DNA extraction kit (Anachem) or by GenoVar Diagnostics (Sittingbourne, UK). Primers were designed using the program Oligo4 (Hybaid, UK) and oligonucleotides synthesised by Genosys Biotechnologies (Europe). The PCR assay to amplify the microsatellite G64931 employed 100 ng of each primer 5Ј CAG AGA AAA GTA TAT GGT ATG GAA C 3Ј and 5Ј AAG GAT ACA GAT TTC AGA ATA GCA G 3Ј. PCR reactions were carried out on a PTC225 (MJ Research) using 50 ng total genomic DNA, 40 ng each primer, 200 M dNTPs (Advanced Biotechnologies), 3 mM MgCl 2 and 0.4 U Amplitaq (Perkin Elmer) in 1× PCR buffer (Perkin Elmer) in a total of 20 l. Products were labelled fluorescently when required by including in the PCR mix 250 nM dCTP labelled with R110 or R6G, or alternatively 1 M dCTP labelled with TAMRA (PE Applied Biosystems). The program used was an initial denaturation of 94°C for 30 s, then 35 cycles of 94°C for 15 s, 56°C for 30 s and 72°C for 30 s. Selected PCR products were checked on 2% agarose gels prior to further analysis. DHPLC DHPLC analysis was carried out on a WAVE™ DNA Fragment Analysis System (Transgenomic, Santa Clara, CA, USA). A total of 10 l of PCR product was denatured at 95°C for 3 min on a thermal cycler and was then permitted to form heteroduplexes by cooling to 30°C at a rate of 0.1°C s ) at a predetermined melting temperature. Gradients were achieved by mixing 0.1 M triethylamine acetate (pH 7.0) with an increasing proportion of 25% acetonitrile; melting temperatures and start and end points of the gradient were dependent on the product length and sequence composition and were determined using the Wavemaker™ software (Transgenomic, Santa Clara, CA, USA).
DNA sequencing
Selected PCR products were purified using a Presequencing kit (Amersham) and sequenced with the original PCR primers on an ABI377 using dRhodamine dye terminators (PE Applied Biosystems) according to the manufacturer's instructions.
Sequence analysis
Sequence chromatograms and BAC sequence fragments were aligned into contigs and viewed using Phred, Phrap and Consed (version 6.0), [27] [28] [29] http://www.genome.washington.edu
Genotyping
To prepare the samples, 0.1-1 l PCR product was mixed with 11.5 l deionised formamide and 0.5 l GENESCAN-350 size marker (PE Applied Biosystems), denatured at 96°C for 5 min and cooled on ice. Samples were then run on an ABI310 according to standard procedures. Resultant traces were manipulated and allele sizes were read using Genescan™ software (PE Applied Biosystems).
